论文部分内容阅读
科兰损伤小组得出结论,除了严格地进行随机对照试验,不应当给危重病病人使用人血白蛋白,Offringa在其所加编者的话中也这佯讲。科兰小组发现,对于有低血容量症、烧伤或低白蛋白血症的危重病病人应用白蛋白可能会增加死亡率。 1997年初,作者审查了应用人血白蛋白(4.5％和20％)溶液。结果表明,4.5％人血白蛋白溶液非特异地用于有各种临床情况(包括1例偶然只请求500ml者)的血清中白蛋白含量低下者;20％人血白蛋白溶液主要用于慢性肝病患者。 在这一审查期间,作者就使用人血白蛋白溶液的适应症问题查阅了文献。作者发现在所查的文献中关于其适应症很少一
The Corran Injury Panel concluded that except for rigorous randomized controlled trials, human albumin should not be used in critically ill patients, as Offringa said in his editorial. The Collan Group found that the administration of albumin may increase mortality in critically ill patients with hypovolemia, burns or hypoalbuminemia. In early 1997, the authors reviewed the use of human albumin (4.5% and 20%) solutions. The results showed that 4.5% human serum albumin solution was used nonspecifically in patients with low serum albumin levels in a variety of clinical settings (including 1 case who only requested 500 ml occasionally); 20% human serum albumin solution was mainly used in chronic liver disease patient. During this review, the authors reviewed the literature on the indication of the use of human albumin solution. The authors found little indication of indications in the literature examined